Medical Guidance Systems LLC
Saint Louis, MO · Biotech · Private
Ligand-targeted liposomes for delivery of therapeutics to non-small cell lung cancer
- Grants
- $3.0M
- 6 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2015201620172018201920202021
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Pegylated Peptides Ligands Targeting Radiation-inducible Receptors On Cancer | $225,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Anti-pdz Domain Antibodies Enhance The Efficacy Of Radiotherapy | $216,853 | |
| Federal grant | Department of Health and Human Services · Phase I · Design and Development of Targeted-Liposome for drug delivery to lung cancer by exploiting a vulnerability induced by radiotherapy | $296,606 | |
| Federal grant | Department of Health and Human Services · Phase I · Design and Development of Targeted-Liposome for drug delivery to lung cancer by exploiting a vulnerability induced by radiotherapy | $296,606 | |
| Federal grant | Department of Health and Human Services · Phase II · Humanization, Production, and PK/PD Characterization of anti-TIP1 antibody against Non-Small Cell Lung Cancer | $1,011,611 | |
| Federal grant | Department of Health and Human Services · Phase II · Humanization, Production, and PK/PD Characterization of anti-TIP1 antibody against Non-Small Cell Lung Cancer | $978,235 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 3099 | ASSUAGE PHARMACEUTICALS, INC. | — | — |
| 3100 | TUNITAS THERAPEUTICS, INC. | — | — |
| 3101 | KL50 THERAPEUTICS, LLC | — | — |
| 3102 | Medical Guidance Systems LLC | — | — |
| 3103 | TRIANGLE THERAPEUTICS INC. | — | — |
| 3104 | Thimble Therapeutics Inc | — | — |
| 3105 | EPIVAX, INC. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.